NEW YORK – The US Food and Drug Administration on Monday approved Regeneron Pharmaceuticals and Sanofi's PD-1 inhibitor cemiplimab-rwlc (Libtayo) as a front-line treatment for advanced non-small cell lung cancer patients with high PD-L1 expression in their tumors.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.